Form Type: 4

SEC EDGAR Link
Accession Number:0001209191-20-007505
Date:2020-02-05
Issuer: VERTEX PHARMACEUTICALS INC / MA (VRTX)
Original Submission Date:

Reporting Person:

PARINI MICHAEL
C/O VERTEX PHARMACEUTICALS INCORPORATED
50 NORTHERN AVENUE BOSTON, MA 02210

Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
Title of SecurityTransaction Date2a. Deemed Execution Date Transaction CodeSharesAcquired or DisposedPrice per share 5. Amount of Securities Beneficially Owned Following Reported Transaction 6. Ownership Form Direct or IndirectNature of Indirect Ownership
COMMON STOCK 2020-02-05 A 18,204 a $0.00 49,757 direct
COMMON STOCK 2020-02-05 A 8,166 a $0.00 57,923 direct
COMMON STOCK 2020-02-05 A 10,323 a $0.00 68,246 direct
COMMON STOCK 2020-02-06 M 1,303 a $187.53 69,549 direct
COMMON STOCK 2020-02-06 M 1,223 a $155.57 70,772 direct
COMMON STOCK 2020-02-06 S 1,487 d $238.77 69,285 direct
COMMON STOCK 2020-02-06 S 585 d $239.58 68,700 direct
COMMON STOCK 2020-02-06 S 300 d $240.79 68,400 direct
COMMON STOCK 2020-02-06 S 154 d $242.47 68,246 direct
Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, convertible securities
Title of Derivative Security Conversion or Exercise Price of Derivative Security Transaction Date Deemed Execution Date Transaction Code Number of Derivative Securities Acquired (A) or Disposed of (D) Date ExercisableExpiration Date Title and Amount of Securities Underlying Derivative Security Price of Derivative Security Number of derivative Securities Beneficially Owned Following Reported Transaction(s) Ownership Form: Direct (D) or Indirect (I) Nature of Indirect Beneficial Ownership
STOCK OPTION (RIGHT TO BUY) 187.53 2020-02-06 deemed execution date M 1,303 (d) 2029-02-05 common stock 1,303 $187.53 15,642 direct
STOCK OPTION (RIGHT TO BUY) 155.57 2020-02-06 deemed execution date M 1,223 (d) 2028-02-05 common stock 1,223 $155.57 9,783 direct
Footnotes
IDfootnote
f1 represents earned performance shares with respect to a performance stock unit award granted on 02/03/2017 that contained performance-vesting requirements. the issuer's management development and compensation committee certified as to the level of performance-goal attainment on 02/05/2020 and the shares will vest on 02/10/2020.
f2 represents earned performance shares with respect to a performance stock unit award granted on 02/06/2019 that contained performance-vesting requirements. the issuer's management development and compensation committee certified as to the level of performance-goal attainment on 02/05/2020. the earned performance shares will vest in installments beginning on 02/24/2020.
f3 restricted stock unit award that vests in installments beginning on 02/10/2021.
f4 transaction made pursuant to mr. parini's company-approved trading plan under rule 10b5-1.
f5 open market sales reported on this line occurred at a weighted average price of $238.77 (range $238.15 to $239.11).
f6 mr. parini undertakes to provide (upon request by the sec staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
f7 open market sales reported on this line occurred at a weighted average price of $239.58 (range $239.17 to $240.11).
f8 open market sales reported on this line occurred at a weighted average price of $240.79 (range $240.51 to $241.05).
f9 the option vests in 16 quarterly installments from 02/06/2019.
f10 the option vests in 16 quarterly installments from 02/06/2018.
WhaleWisdom Logo

Elevate your investments